Table 1.
TNFR-targeted agents in development
| TNF receptor molecule | Name | Description | Sponsor | Phase in cancer patients |
|---|---|---|---|---|
| 4-1BB (CD137) |
CART19 cells |
T cells transduced with antibody against CD19 linked to the intracellular signaling domains of 4-1BB and CD3-zeta |
University of Pennsylvania and others |
II |
| Urelumab |
Fully human anti-CD137 agonist monoclonal antibody |
Bristol Myers-Squibb |
I |
|
| OX40 |
|
Mouse monoclonal anti-OX40 agonist antibody |
Providence Health & Services and others |
II |
| |
Humanized antibody against OX40 |
|
Preclinical |
|
| hFcILZOX40L |
Recombinant human Fc:OX40L fusion protein |
Providence Portland Medical Center |
Preclinical |
|
| GITR |
TRX518 |
Humanized anti-GITR agonist monoclonal antibody |
GITR, Inc. |
I |
| GITRL RNA DC |
GITRL-expressing DCs |
Duke University |
I |
|
| CD27 | CDX-1127 | Fully human anti-CD27 agonist monoclonal antibody | Celldex Therapeutics | I |
Abbreviation: DCs Dendritic Cells, GITR Glucocorticoid-Induced TNFR-Related Gene, GITRL GITR Ligand, TNF Tumor-Necrosis Factor, TNFR Tumor-Necrosis Factor Receptor.